Form 4: Esperion CFO Sells Shares for Tax Obligation
Insider Transaction Report
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 7,337 shares of common stock to cover tax obligations on vested restricted stock units.
Summary
- Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc. (ESPR), reported a sale of common stock.
- The transaction involved the disposition of 7,337 shares of Esperion Therapeutics, Inc. common stock.
- The shares were sold at a price of $3.667 per share.
- The sale was conducted to satisfy tax obligations on vested restricted stock units.
- Following this transaction, Benjamin Halladay beneficially owns 467,525 shares of common stock.
- The transaction is dated December 17, 2025, indicating a future planned sale, likely under a Rule 10b5-1 plan.
- The filing was signed by Sheldon L. Koenig by power of attorney on December 18, 2025.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider sale to cover tax obligations on vested equity, which is a neutral event from an operational or strategic perspective. It does not indicate any change in company fundamentals or management's view of the company's prospects.
Future Outlook
The filing indicates a pre-planned future transaction for December 17, 2025, suggesting a structured approach to managing equity compensation and tax liabilities.
Industry Context
Insider sales to cover tax obligations on vested equity awards are a common and routine occurrence across all industries, particularly in biotechnology and pharmaceutical companies like Esperion Therapeutics, where executive compensation often includes significant equity components.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization | Benjamin Halladay granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker, effective November 16, 2022, authorizing them to execute and file SEC forms (including Forms ID, 3, 4, 5, and Schedule 13D) on his behalf as an officer and/or director of Esperion Therapeutics, Inc. | November 16, 2022 | This streamlines the process for the Chief Financial Officer to comply with SEC reporting requirements for insider transactions and beneficial ownership, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in the CFO's direct holdings, but it is a routine tax-related event and not indicative of a change in confidence. The overall impact on shareholder value is negligible.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| November 16, 2022 | Benjamin Halladay granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker for SEC filings. |
| December 17, 2025 | Transaction date for the sale of 7,337 shares of common stock. |
| December 18, 2025 | Date the Form 4 was signed and filed. |
Keywords
Esperion Therapeutics, ESPR, Benjamin Halladay, CFO, Insider Trading, Form 4, Stock Sale, Tax Obligation, Restricted Stock Units, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.